Hypoadiponectinemia and aldosterone excess are associated with lack of blood pressure control in subjects with resistant hypertension

Hypertension Research

Volumn 36, Issue 12, 2013, Pages 1067-1072

  De Faria, Ana P C ^a   Demacq, Caroline ^b   Figueiredo, Valéria N ^a   Moraes, Carolina H ^a   Santos, Rodrigo C ^a   Sabbatini, Andréa R ^a   Barbaro, Natália R ^a   Boer Martins, Leandro ^b   Fontana, Vanessa ^a   Moreno Jr , Heitor ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Cardiovascular and Metabolism Unit   (Brazil)

Author keywords

adiponectin; aldosterone; arterial stiffness; obesity; resistant hypertension

Indexed keywords

ADIPONECTIN; ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SPIRONOLACTONE;

ADULT; AGE DISTRIBUTION; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; ARTERY ENDOTHELIUM; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; BRACHIAL ARTERY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; FEMALE; FLOW MEDIATED DILATION; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; HYPOADIPONECTINEMIA; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PULSE PRESSURE; PULSE WAVE; RESISTANT HYPERTENSION; SODIUM RESTRICTION;

ADIPONECTIN; AGE FACTORS; BLOOD CHEMICAL ANALYSIS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; DRUG RESISTANCE; ECHOCARDIOGRAPHY; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; LINEAR MODELS; MALE; MIDDLE AGED; SEX FACTORS;

EID: 84890091120     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2013.92     Document Type: Article

References (37)

1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: Diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403-1419
2. Quinaglia T, Martins LC, Figueiredo VN, Santos RC, Yugar-Toledo JC, Martin JF, Demacq C, Pimenta E, Calhoun DA, Moreno H Jr. Non-dipping pattern relates to endothelial dysfunction in patients with uncontrolled resistant hypertension. J Hum Hypertens 2011; 25: 656-664
3. Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins L, Yugar-Toledo JC, Martin JF, Demacq C, Pimenta E, Calhoun DA, Moreno H Jr. Characteristics of resistant hypertension: Ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. J Hum Hypertens 2011; 25: 532-538
4. Yugar-Toledo JC, Tanus-Santos JE, Sabha M, Sousa MG, Cittadino M, Tacito LH, Moreno H Jr. Uncontrolled hypertension, uncompensated type II diabetes, and smoking have different patterns of vascular dysfunction. Chest 2004; 125: 823-830
5. Pabuccu T, Baris N, Ozpelit E, Akdeniz B, Guneri S. The relationship between resistant hypertension and arterial stiffness. Clin Exp Hypertens 2011; 34: 57-62
6. Kotchen TA, Grim CE, Kotchen JM, Krishnaswami S, Yang H, Hoffmann RG, McGinley EL. Altered relationship of blood pressure to adiposity in hypertension. Am J Hypertens 2008; 21: 284-289
7. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009; 150: 776-783
8. Frayn KN, Karpe F, Fielding BA, Macdonald IA, Coppack SW. Integrative physiology of human adipose tissue. Int J Obes Relat Metab Disord 2003; 27: 875-888
9. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, Fu Y, Motone M, Yamamoto K, Matsuo A, Ohashi K, Kihara S, Funahashi T, Rakugi H, Matsuzawa Y, Ogihara T. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004; 43: 1318-1323
10. Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH, Ong LH, Tam S, Tan KC, Janus ED, Lam TH, Lam KS. Hypoadiponectinemia as a predictor for the development of hypertension: A 5-year prospective study. Hypertension 2007; 49: 1455-1461
11. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003; 16: 72-75
12. de Souza WA, Sabha M, de Faveri Favero F, Bergsten-Mendes G, Yugar-Toledo JC, Moreno H. Intensive monitoring of adherence to treatment helps to identify 'true' resistant hypertension. J Clin Hypertens 2009; 11: 183-191
13. Groppelli A, Omboni S, Parati G, Mancia G. Evaluation of noninvasive blood pressure monitoring devices Spacelabs 90202 and 90207 versus resting and ambulatory 24-hour intra-Arterial blood pressure. Hypertension 1992; 20: 227-232
14. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083
15. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-265
16. Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, Target R, Levy BI. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 1995; 26: 485-490
17. Christensen KL. Reducing pulse pressure in hypertension may normalize small artery structure. Hypertension 1991; 18: 722-727
18. Elzinga G, Westerhof N. Pressure and flow generated by the left ventricle against different impedances. Circ Res 1973; 32: 178-186
19. Youn JC, Kim C, Park S, Lee SH, Kang SM, Choi D, Son NH, Shin DJ, Jang Y. Adiponectin and progression of arterial stiffness in hypertensive patients. Int J Cardiol 2011; 163: 316-319
20. Mahmud A, Feely J. Adiponectin and arterial stiffness. Am J Hypertens 2005; 18: 1543-1548
21. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278: 45021-45026
22. Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, Kumada M, Okamoto Y, Nagaretani H, Nishizawa H, Kishida K, Komuro R, Ouchi N, Kihara S, Nagai R, Funahashi T, Matsuzawa Y. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002; 277: 37487-37491
23. Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adiponectin: Molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond) 2008; 114: 361-374
24. Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H, Kumada M, Ohashi K, Okamoto Y, Nishizawa H, Kishida K, Maeda N, Nagasawa A, Kobayashi H, Hiraoka H, Komai N, Kaibe M, Rakugi H, Ogihara T, Matsuzawa Y. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003; 42: 231-234
25. Hong SJ, Park CG, Seo HS, Oh DJ, Ro YM. Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood Press 2004; 13: 236-242
26. Wilkinson IB, MacCallum H, Cockcroft JR, Webb DJ. Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity in vivo. Br J Clin Pharmacol 2002; 53: 189-192
27. Figueiredo VN, Yugar-Toledo JC, Martins LC, Martins LB, de Faria AP, de Haro Moraes C, Sierra C, Coca A, Moreno H. Vascular stiffness and endothelial dysfunction: Correlations at different levels of blood pressure. Blood Press 2012; 21: 31-38
28. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981; 304: 930-933
29. de Haro Moraes C, Figueiredo VN, de Faria AP, Barbaro NR, Sabbatini AR, Quinaglia T, Ferreira-Melo SE, Martins LC, Demacq C, Junior HM. High-circulating leptin levels are associated with increased blood pressure in uncontrolled resistant hypertension. J Hum Hypertens 2012; 27: 225-230
30. Li P, Zhang XN, Pan CM, Sun F, Zhu DL, Song HD, Chen MD. Aldosterone perturbs adiponectin and PAI-1 expression and secretion in 3T3-L1 adipocytes. Horm Metab Res 2011; 43: 464-469
31. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, Li J, Williams GH, Adler GK. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-Activated receptor-gamma, and proinflammatory adipokines. Circulation 2008; 117: 2253-2261
32. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71: 12A-16A.
33. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: A randomized trial. JAMA 2003; 289: 1799-1804
34. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, Scherer PE. Structure-function studies of the adipocyte-secreted hormone Acrp30/ adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 2003; 278: 9073-9085
35. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002; 290: 1084-1089
36. Yamada S, Ano N, Toda K, Kitaoka A, Shiono K, Inoue G, Atsuda K, Irie J. Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro. Hypertens Res 2008; 31: 601-606
37. Yilmaz MI, Sonmez A, Caglar K, Celik T, Yenicesu M, Eyileten T, Acikel C, Oguz Y, Yavuz I, Vural A. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology 2007; 12: 147-153